Poorina AHMADİ
(Tahran Tıp Bilimleri Üniversitesi Vali-Asr Hastanesi, İmam Humeyni Kompleksi Hastanesi, Endokrinoloji ve Metabolizma Araştırma Merkezi, Endokrinoloji Anabilim Dalı, Tahran, İran)
(Tahran Tıp Bilimleri Üniversitesi Endokrinoloji ve Metabolizma Klinik Bilimler Enstitüsü, Endokrinoloji ve Metabolizma Araştırma Merkezi, Tahran, İran)
(Tahran Tıp Bilimleri Üniversitesi, İmam Humeyni Kompleksi Hastanesi, Patoloji Anabilim Dalı, Tahran, İran)
(Tahran Tıp Bilimleri Üniversitesi Vali-Asr Hastanesi, İmam Humeyni Kompleksi Hastanesi, Endokrinoloji ve Metabolizma Araştırma Merkezi, Endokrinoloji Anabilim Dalı, Tahran, İran)
Yıl: 2021Cilt: 22Sayı: 1ISSN: 2619-9793 / 2148-094XSayfa Aralığı: 61 - 67İngilizce

45 0
Insulinoma: Spectrum of Clinicopathological Features in a Tertiary Center
Introduction: Insulinoma is the most common functional neuroendocrine tumor of the pancreas. There are different methods for the preoperative localization of insulinoma, such as Computed Tomography (CT) scan, Magnetic Resonance Imaging and Endoscopic Ultra Sonography (EUS). In this study, we report on the clinicopathological features of insulinoma in 43 patients. Methods: The hospital records of 43 patients with suspicion of insulinoma based on biochemical diagnostic criteria, referred to İmam Khomeini Complex Hospital, Tehran, Iran between 2006 and 2016, were reviewed retrospectively. Results: Of the 43 studied patients, 28 were female. The mean age of the patients was 45.4±13.3 years. The most frequent clinical presentation of insulinoma was neurogenic and neuroglycopenic symptoms (81.4%). Mean glucose, insulin, and C-peptide in patients with hypoglycemic crisis were 39.13±13.15 mg/dL, 32.15±32.53 μUI/mL, and 4.77±2.88 ng/mL, respectively. Mean tumor size was 2.13±1.22 cm. The most common site of insulinoma was the tail of the pancreas. Surgery was the treatment of choice and performed in 31 patients. Of 21 tumors studied microscopically, 7 were invasive. Conclusion: In non-diabetic patients with manifestations of hypoglycemia, a diagnosis of insulinoma should be considered. During the past decade, the diagnostic delay for insulinoma has been reduced in our country by improving imaging technologies. EUS and CT scan are the best modalities for localization and size measurement of insulinoma. Tumor size has decreased compared with pre
DergiAraştırma MakalesiErişime Açık
  • 1. Khagi S, Saif MW. Pancreatic neuroendocrine tumors: targeting the molecular basis of disease. Curr Opin Oncol 2015; 27: 38-43.
  • 2. Fraenkel M, Kim MK, Faggiano A, Valk GD. Epidemiology of gastroenteropancreatic neuroendocrine tumours. Best Pract Res Clin Gastroenterol 2012; 26: 691-703.
  • 3. Ito T, Igarashi H, Nakamura K, Sasano H, Okusaka T, Takano K, et al. Epidemiological trends of pancreatic and gastrointestinal neuroendocrine tumors in Japan: a nationwide survey analysis. J Gastroenterol 2015; 50: 58- 64.
  • 4. Boyar Cetinkaya R, Aagnes B, Thiis-Evensen E, Tretli S, Bergestuen DS, Hansen S. Trends in Incidence of Neuroendocrine Neoplasms in Norway: A Report of 16,075 Cases from 1993 through 2010. Neuroendocrinology 2017; 104: 1-10.
  • 5. Zhao YP, Zhan HX, Zhang TP, Cong L, Dai MH, Liao Q, et al. Surgical management of patients with insulinomas: Result of 292 cases in a single institution. J Surg Oncol 2011; 103: 169-74.
  • 6. Turaga KK, Kvols LK. Recent progress in the understanding, diagnosis, and treatment of gastroenteropancreatic neuroendocrine tumors. CA Cancer J Clin 2011; 61: 113-32.
  • 7. Service FJ, McMahon MM, O’Brien PC, Ballard DJ. Functioning insulinoma- -incidence, recurrence, and long-term survival of patients: a 60-year study. Mayo Clin Proc 1991; 66: 711-9.
  • 8. Rostambeigi N, Thompson GB. What should be done in an operating room when an insulinoma cannot be found? Clin Endocrinol (Oxf) 2009; 70: 512-5.
  • 9. Oberg K, Eriksson B. Endocrine tumours of the pancreas. Best Pract Res Clin Gastroenterol 2005; 19: 753-81.
  • 10. Vaidakis D, Karoubalis J, Pappa T, Piaditis G, Zografos GN. Pancreatic insulinoma: current issues and trends. Hepatobiliary Pancreat Dis Int 2010; 9: 234-41.
  • 11. Shin JJ, Gorden P, Libutti SK. Insulinoma: pathophysiology, localization and management. Future Oncol 2010; 6: 229-37.
  • 12. Iglesias P, Díez JJ. Management of endocrine disease: a clinical update on tumor-induced hypoglycemia. Eur J Endocrinol 2014; 170: 147-57.
  • 13. Cheng Y, Zhan H, Wang L, Xu J, Zhang G, Zhang Z, et al. Analysis of 100 consecutive cases of resectable pancreatic neuroendocrine neoplasms: clinicopathological characteristics and long-term outcomes. Front Med 2016; 10: 444-50.
  • 14. Yu R, Nissen NN, Hendifar A, Tang L, Song YL, Chen YJ, et al. A Clinicopathological Study of Malignant Insulinoma in a contemporary series. Pancreas 2017; 46: 48-56.
  • 15. Peltola E, Hannula P, Huhtala H, Metso S, Kiviniemi U, Vornanen M, et al. Characteristics and Outcomes of 79 Patients with an Insulinoma: A Nationwide Retrospective Study in Finland. Int J Endocrinol 2018; 2018: 2059481.
  • 16. Larijani B, Aghakhani S, Lor SS, Farzaneh Z, Pajouhi M, Bastanhagh MH. Insulinoma in Iran: a 20-year review. Ann Saudi Med 2005; 25: 477-80.
  • 17. Goh BK, Ooi LL, Cheow PC, Tan YM, Ong HS, Chung YF, et al. Accurate preoperative localization of insulinomas avoids the need for blind resection and reoperation: analysis of a single institution experience with 17 surgically treated tumors over 19 years. J Gastrointest Surg 2009; 13: 1071-7.
  • 18. Tsang YP, Lang BH, Shek TW. Assessing the short- and long-term outcomes after resection of benign insulinoma. ANZ J Surg 2016; 86: 706-10.
  • 19. Iglesias P, Lafuente C, Martín Almendra MÁ, López Guzmán A, Castro JC, Díez JJ. Insulinoma: A multicenter, retrospective analysis of three decades of experience (1983-2014). Endocrinol Nutr 2015; 62: 306-13.
  • 20. Hackert T, Hinz U, Fritz S, Strobel O, Schneider L, Hartwig W, et al. Enucleation in pancreatic surgery: indications, technique, and outcome compared to standard pancreatic resections. Langenbecks Arch Surg 2011; 396: 1197-203.
  • 21. Vig S, Lewis M, Foster KJ, Stacey-Clear A. Lessons to be learned: a case study approach insulinoma presenting as a change in personality. J R Soc Promot Health 2001; 121: 56-61.
  • 22. Marek B, Kajdaniuk D, Kos-Kudła B, Foltyn W, Borgiel-Marek H, Matyja V, et al. Insulinoma: diagnosis and treatment. Endokrynol Pol 2007; 58: 58-62.
  • 23. Cryer PE, Axelrod L, Grossman AB, Heller SR, Montori VM, Seaquist ER, et al. Evaluation and management of adult hypoglycemic disorders: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 2009; 94: 709-28.
  • 24. Guettier JM, Kam A, Chang R, Skarulis MC, Cochran C, Alexander HR, et al. Localization of insulinomas to regions of the pancreas by intra arterial calcium stimulation: the NIH experience. J Clin Endocrinol Metab 2009; 94: 1074-80.
  • 25. Grant CS. Insulinoma. Best Pract Res Clin Gastroenterol 2005; 19: 783-98.
  • 26. Mehrabi A, Fischer L, Hafezi M, Dirlewanger A, Grenacher L, Diener MK, et al. A systematic review of localization, surgical treatment options, and outcome of insulinoma. Pancreas 2014; 43: 675-86.
  • 27. de Herder WW, Niederle B, Scoazec JY, Pauwels S, Kloppel G, Falconi M, et al. Well-differentiated pancreatic tumor/carcinoma: insulinoma. Neuroendocrinology 2006; 84: 183-8.
  • 28. Jensen RT, Cadiot G, Brandi ML, de Herder WW, Kaltsas G, Komminoth P, et al. ENETS consensus guidelines for the management of patients with digestive neuroendocrine neoplasms: functional pancreatic endocrine tumor syndromes. Neuroendocrinology 2012; 95: 98-119.
  • 29. Taye A, Libutti S. Diagnosis and management of insulinoma: current best practice and ongoing developments. Research and Reports in Endocrine Disorders 2015; 5: 125-33.
  • 30. Okabayashi T, Shima Y, Sumiyoshi T, Kozuki A, Ito S, Ogawa Y, et al. Diagnosis and management of insulinoma. World J Gastroenterol 2013; 19: 829-37.
  • 31. B Baudin E, Caron P, Lombard-Bohas C, Tabarin A, Mitry E, Reznick Y, et al. Malignant insulinoma: recommendations for characterisation and treatment. Ann Endocrinol (Paris) 2013; 74: 523-33.

TÜBİTAK ULAKBİM Ulusal Akademik Ağ ve Bilgi Merkezi Cahit Arf Bilgi Merkezi © 2019 Tüm Hakları Saklıdır.